During the 2020 ACR State-of-the-Art Clinical Symposium, Zoltán Szekanecz, MD, PhD, addressed the risks of vascular disease and how to manage them in patients with rheumatic diseases.
Risk Assessment & Treatment in APS Patients
The pathogenesis of antiphospholipid syndrome (APS) is complicated and may involve local inflammation, vasculopathy, pregnancy complications and thrombosis. During the 2019 ACR State-of-the-Art Clinical Symposium, Lisa Sammaritano, MD, addressed the risk assessment and treatment of APS patients…
Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
CHICAGO—Doruk Erkan, MD, MPH, a rheumatologist at the Hospital for Special Surgery and Weill Cornell Medicine in New York City, described recent developments in the field of antiphospholipid syndrome (APS) to the rheumatologists gathered for the ACR’s State-of-the-Art Clinical Symposium in April. He introduced APS as a “field with limited data and lots of controversies,” although,…
APS: What Rheumatologists Should Know about Hughes Syndrome
The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…
ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)
CAPS is a rare, complex disease which involves sudden clotting on multiple fronts